CogstateCOGZF 90 ROA % is 13.66% as of Dec. 2025, which is 68% above its 10-year median of 8.14. GuruFocus rates COGZF with a GF Score™ of 90/100 and a GF Value™ of $1.57 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 686 Healthcare Providers & Services companies, Cogstate ranks better than 95.48% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Cogstate's annualizedNet Income for the quarter that ended in Dec. 2025 was $9.07 Mil.
Cogstate's average Total Assets over the quarter that ended in Dec. 2025 was $66.39 Mil. Therefore, Cogstate's annualized ROA % for the quarter that ended in Dec. 2025 was 13.66%.
The historical rank and industry rank for Cogstate's ROA % or its related term are showing as below:
COGZF'
s ROA % Range Over the Past 10 Years
Min: -13.62 Med: 8.14 Max: 16.7
Current: 16.55
During the past 13 years, Cogstate's highest ROA % was 16.70%. The lowest was -13.62%. And the median was 8.14%.
COGZF's ROA % is ranked better than 95.48% of 686
companies
in the Healthcare Providers & Services industry
Industry Median: 1.75
vs COGZF: 16.55
Cogstate (OTCPK:COGZF) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Cogstate ROA % Related Terms
Cogstate ROA % Historical Data
* Premium members only.
The historical data trend for Cogstate's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Cogstate's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogstate ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's ROA % distribution charts can be found below:
* The bar in red indicates where Cogstate's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Cogstate (COGZF) has a ROA % of 13.66% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Cogstate and its competitors. This is 68% above median its historical median of 8.14. According to the industry distribution chart, Cogstate ranks #31 out of 686 companies in the Healthcare Providers & Services industry, placing it in the top 4.5%.
Is Cogstate's ROA % too high?
Cogstate's current ROA % of 13.66% is 68% above median its 10-year median of 8.14. The Healthcare Providers & Services industry median ROA % is 1.75. Cogstate's value of 13.66% is 680.6% above this industry median. Based on the distribution chart, Cogstate ranks #31 out of 686 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cogstate has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's ROA % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cogstate ranks #31 out of 686 companies for ROA %. This places Cogstate in the top 5% of its industry — outperforming the majority of peers. The industry median ROA % is 1.75. Cogstate's value of 13.66% is 680.6% above this benchmark. While the company's 10-year median is 8.14 vs. the industry median of 1.75, Cogstate has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.75, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogstate's current ROA % of 13.66% is 680.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Cogstate and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogstate's current ROA % is 13.66%, which is 68% above median its own 10-year median of 8.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (COGZF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.57, compared to a current price of $1.89 — trading 20.4% above its estimated fair value. The current ROA % is 13.66%, which is 68% above median its 10-year median of 8.14 and 680.6% above the Healthcare Providers & Services industry median of 1.75. Cogstate's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Cogstate (COGZF), the current ROA % is 13.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cogstate (COGZF) Overvalued in 2026?
Based on GuruFocus' analysis, Cogstate stock appears to be overvalued.
The current stock price of $1.89 is trading 20.4% above its estimated GF Value™ of $1.57.
GuruFocus considers Cogstate to be Modestly Overvalued.
Key valuation signals for COGZF:
ROA %: 13.66% (68% above median its 10-year median of 8.14)
GF Value™: $1.57 vs. price of $1.89 (20.4% above fair value)
Industry Position: 680.6% above the Healthcare Providers & Services median (#31 of 686)
No single metric tells the full story. See the COGZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
90GF Score
Get the complete analysis for COGZF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGZF has been successfully added to your 
